Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ

被引:281
作者
Wang, DZ
Wang, HB
Shi, Q
Katkuri, S
Walhi, W
Desvergne, B
Das, SK
Dey, SK
DuBois, RN [1 ]
机构
[1] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA
[4] Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA
[5] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA
[6] Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA
[7] Univ Lausanne, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland
关键词
D O I
10.1016/j.ccr.2004.08.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cyclooxygenase-derived prostaglandin E-2 (PGE(2)) is the predominant prostanoid found in most colorectal cancers (CRC) and is known to promote colon carcinoma growth and invasion. However, the key downstream signaling pathways necessary for PGE(2)-induced intestinal carcinogenesis are unclear. Here we report that PGE(2) indirectly transactivates PPARdelta through PI3K/Akt signaling, which promotes cell survival and intestinal adenoma formation. We also found that PGE2 treatment of Apc(min) mice dramatically increased intestinal adenoma burden, which was negated in Apc(min) mice lacking PPARdelta. We demonstrate that PPARdelta is a focal point of crosstalk between the prostaglandin and Wnt signaling pathways which results in a shift from cell death to cell survival, leading to increased tumor growth.
引用
收藏
页码:285 / 295
页数:11
相关论文
共 47 条
[11]   Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis [J].
Giardiello, FM ;
Casero, RA ;
Hamilton, SR ;
Hylind, LM ;
Trimbath, JD ;
Geiman, DE ;
Judge, KR ;
Hubbard, W ;
Offerhaus, GJA ;
Yang, VW .
GASTROENTEROLOGY, 2004, 126 (02) :425-431
[12]   Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer [J].
Gupta, RA ;
Tan, J ;
Krause, WF ;
Geraci, MW ;
Willson, TM ;
Dey, SK ;
DuBois, RN .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (24) :13275-13280
[13]   Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 [J].
Gupta, RA ;
DuBois, RN .
NATURE REVIEWS CANCER, 2001, 1 (01) :11-21
[14]   Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth [J].
Gupta, RA ;
Wang, DZ ;
Katkuri, S ;
Wang, HB ;
Dey, SK ;
DuBois, RN .
NATURE MEDICINE, 2004, 10 (03) :245-247
[15]   A dominant-negative peroxisome proliferator-activated receptor γ (PPARγ) mutant is a constitutive repressor and inhibits PPARγ-mediated adipogenesis [J].
Gurnell, M ;
Wentworth, JM ;
Agostini, M ;
Adams, M ;
Collingwood, TN ;
Provenzano, C ;
Browne, PO ;
Rajanayagam, O ;
Burris, TP ;
Schwabe, JW ;
Lazar, MA ;
Chatterjee, VKK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (08) :5754-5759
[16]  
Hansen-Petrik MB, 2002, CANCER RES, V62, P403
[17]   Peroxisome proliferator-activated receptor δ activation promotes cell survival following hypertonic stress [J].
Hao, CM ;
Redha, R ;
Morrow, J ;
Breyer, MD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (24) :21341-21345
[18]   Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis [J].
Harman, FS ;
Nicol, CJ ;
Marin, HE ;
Ward, JM ;
Gonzalez, FJ ;
Peters, JM .
NATURE MEDICINE, 2004, 10 (05) :481-483
[19]   Identification of c-MYC as a target of the APC pathway [J].
He, TC ;
Sparks, AB ;
Rago, C ;
Hermeking, H ;
Zawel, L ;
da Costa, LT ;
Morin, PJ ;
Vogelstein, B ;
Kinzler, KW .
SCIENCE, 1998, 281 (5382) :1509-1512
[20]   PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs [J].
He, TC ;
Chan, TA ;
Vogelstein, B ;
Kinzler, KW .
CELL, 1999, 99 (03) :335-345